Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.

Slides:



Advertisements
Similar presentations
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà
Advertisements

Ronald A. Codario, MD Assistant Clinical Professor of Medicine
Immune Activation/Inflammation and HIV Disease Prof. Georg Behrens Department for Clinical Immunology and Rheumatology Hannover Medical School Germany.
Apex Block III, delkurs IV HT 2006
Angelo Avogaro Università degli Studi di Padova La carenza di cellule endoteliali progenitrici: un passaggio chiave nell’ambito della patologia cardiovascolare.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Adiposity in CVD. Role of adipose tissue in atherogenesis Adapted from de Luca C, Olefsky JM. Nat Med. 2006;12:41-2. Lau DCW et al. Am J Physiol Heart.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Source: International Chair on Cardiometabolic Risk Abdominal Obesity, Intra-abdominal Adiposity and Related Cardiometabolic.
Risk factors of Heart disease Dr. Mahmoudian.. Risk factors for coronary artery atherosclerosis Hyperlipidemia and dyslipidemia Hypertension Cigarette.
Diabetic Dyslipidemia and Atherosclerosis Henry Ginsberg, MD
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
Global impact of ischemic heart disease World Heart Federation, 2011.
METABOLIC Syndrome: a Global Perspective
10th Meeting of the Mediterranean Group for the Study of Diabetes Istanbul – April 26-29, 2007 Lung dysfunctions in Metabolic Syndrome and Diabetes Prof.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
DYSLIPIDEMIAS: TYPES I-V Thomas F. Whayne, Jr, MD, PhD, FACC Professor of Medicine (Cardiology) University of Kentucky March 2011.
cardio protection: Focus on
Towards better screening of CV risk Paul Ridker MD Associate Professor of Medicine Division of Preventive Medicine and Cardiovascular Diseases Harvard.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
STEVIA SYMPOSIUM LEUVEN July 2009 EFFECT OF STEVIOSIDE ON ATHEROSCLEROSIS IN A MOUSE MODEL OF THE METABOLIC SYNDROME Paul Holvoet Atherosclerosis and Metabolism.
The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Part 3 Stan Schwartz MD, FACP, FACE.
Plasminogen-Activating Inhibitor-1 (PAI-1) High PAI-1 associated with: Obesity (especially visceral), possible fatty liver. 2,3,4 Inflammation and oxidative.
Cardiometabolic Syndrome Nabil Sulaiman HOD Family and Community Medicine, Sharjah University and University of Melbourne & Dr Dhafir A. Mahmood Consultant.
Metabolic syndrome from a gender and cardiovascular perspective Eva Swahn.
Contemporary Management of Cardiometabolic Risk. A continuing epidemic: 2 of 3 US adults are overweight or obese National Health and Nutrition Examination.
Chapter 15 Cardiovascular Disease Risk Factors and Physical Activity.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
IR and Hyperinsulinemia Insulin Resistance: A Survival Mechanism, Gone Awry Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical.
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C
 2010 Cengage-Wadsworth Preventing Cardiovascular Disease Chapter 11.
Diabetes Mellitus Type 2
METABOLIC SYNDROME Lajos Szollár Professor of Pathophysiology Semmelweis University, Faculty of Medicine Institute of Pathophysiology 2007 METABOLIC SYNDROME.
Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà.
Vascular effects of PPAR  activation: Inflammation.
Insulin Resistance Progression to Diabetes Part 3.
Framingham and the Muddy Waters Jeffry N. Gerber, MD Denver’s Diet Doctor.
HANDBOOK OF DYSLIPIDEMIA AND ATHEROSCLEROSIS Part One Professor Jean-Charles Fruchart Department of Atherosclerosis (Inserm UR545) Pasteur Institute of.
Source: International Chair on Cardiometabolic Risk Metabolic Syndrome and Adipose Tissue Yuji Matsuzawa, MD, PhD Director.
Metabolic Syndrome Endocrine Block 1 Lecture Dr. Usman Ghani.
Epidemiology of Inflammatory Markers and CHD: Evidence for High-Sensitivity C-Reactive Protein Paul M. Ridker, MD, MPH.
Source: International Chair on Cardiometabolic Risk Impact of Obesity on Cardiometabolic Risk: Will We Lose the Battle? Richard.
Abstract The metabolic syndrome (MetS) has surpassed smoking as the number one cause of cardiovascular deaths in the US. However, it remains under diagnosed.
Cardiovascular Disease: Risk Factors and Risk Assessment
Novel insights into regulation of plasma triglyceride levels
The role of unknown risk factors in coronary heart disease
Endocrine Block 1 Lecture Dr. Usman Ghani
Endocrine Block Dr. Usman Ghani
Elevated Circulating Levels of Inflammatory Markers in
By Dr. Sumbul Fatma Clinical Chemistry Unit Department of Pathology
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Phenotype vs. Genotype: Defining Severe Familial Hypercholesterolemia
The relation between venous and arterial thrombosis
Endocrine Block 1 Lecture Dr. Usman Ghani
Cardiovascular Disease Risk in Patients with Rheumatic Diseases
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
Back to the Basics of Dyslipidemia
Vascular biology of metabolic syndrome
Type 2 diabetes: Overlap of clinical conditions
Advanced Nutrition Diet and Cardiovascular Disease 1
THE ENDOCANNABINOID SYSTEM AND CARDIOMETABOLIC RISK
OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.
Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era  Faustino R. Pérez-López,
Section overview: Cardiometabolic risk reduction
CHD RISK Glycemia 75g OGTT Time Metabolic Syndrome
Circulating serum inflammatory markers, a) neutrophils, b) platelets, c) fibrinogen and d) C-reactive protein (CRP), in patients with chronic airflow obstruction.
Several genetic, environmental, lipid partitioning, and biochemical factors, shown on the left, promote the development of subclinical inflammation and.
Presentation transcript:

Grazie per aver scelto di utilizzare a scopo didattico questo materiale delle Guidelines 2011 libra. Le ricordiamo che questo materiale è di proprietà dell’autore e fornito come supporto didattico per uso personale.

Diabetes obesity in patients with COPD Angelo Avogaro

Atherogenic dyslipidemia  Triglycerides  HDL-cholesterol  Cholesterol/HDL-cholesterol ratio "Normal" LDL-cholesterol but  apo B Small, dense LDL and HDL Postprandial hyperlipidemia Insulin resistance Hyperinsulinemia Hyperglycemia Type 2 diabetes Thrombotic state  PAI-1  Fibrinogen Inflammatory state  CRP  Cytokines  risk of acute coronary syndrome Metabolic risk factorsAbdominal obesity Inflammation Lipid core Thin fibrous cap CORONARY ATHEROSCLEROSIS UNSTABLE PLAQUE Intra-abdominal Obesity, Metabolic Risk Factors and CHD adapted from Despres, 2004

Adverse cardiometabolic effects of products of adipocytes Adipose tissue ↑ IL-6 ↓ Adiponectin ↑ Leptin ↑ TNF α ↑ Adipsin (Complement D) ↑ Plasminogen activator inhibitor-1 (PAI-1) ↑ Resistin ↑ FFA ↑ Insulin ↑ Agiotensinogen ↑ Lipoprotein lipase ↑ Lactate Inflammation Type 2 diabetes Hypertension Atherogenic dyslipidaemia Thrombosis Atherosclerosis Lyon 2003; Trayhurn et al 2004; Eckel et al 2005

2001

COPD Inflammation May Contribute to Cardiovascular Disease Rennard. Proc Am Thorac Soc. 2005;2:

38 COPD patients (age: 66 +/- 7 years, [mean +/- SD], FEV1: 43 +/- 16% 34 control participants matched for age and gender are included in this study. RESULTS: 47% of COPD patients and 21% of control participants presented metabolic syndrome. CONCLUSIONS: The presence of metabolic syndrome is frequent in patients with COPD who participated in a cardiopulmonary program. Hence, this population should be considered for screening for the metabolic syndrome. Marquis K et al, J Cardiopulm Rehabil The metabolic syndrome in patients with chronic obstructive pulmonary disease

Peak YJ at al, Metabolism 2010

Log-transformed (log) hs-CRP (A), log interleukin-6 (B), fibrinogen (C), and physical activity level (D) according to GOLD stages and the absence or presence of the metabolic syndrome. Watz H et al. Chest 2009;136:

11 Visceral adipose tissue favours systemic inflammation Visceral tissue area (cm 2 ) Waist girth (cm) , ,2 1,2,3 Quintiles of PCR (1)(2)(3)(4)(5)(1)(2)(3)(4)(5) Lemieux I et al. Arterioscler Thromb Vasc Biol 2001;21: Quintiles of PCR

Sleep Disorders-Metabolic Syndrome Sleep Fragmentation Sleep Deprivation Intermittent Hypoxemia Increased Sympathetic Drive Sleep Disorders Metabolic Syndrome

Homeostasis model assessment in Respiratory Distress Syndrome Punjabi, N. M. et al. Am. J. Epidemiol : ; doi: /aje/kwh26

van Buul, J. D. et al. Arterioscler Thromb Vasc Biol 2004;24: Schematic overview of the distinct steps that comprise leukocyte transendothelial migration

Cardiovascular Health Risk Factors Rescue Factors HDL cholesterol Anti oxidant reserves Endothelial progenitor cells Cigarette smoking Diabetes Mellitus Hypercholesterolemia Hypertension Obesity Age Family history of CVD Gender Postprandial Hyperglycemia

Risk factors Apoptosis Regeneration EPC Endothelial cell apoptosis and -regeneration

The biological significance of EPCs What they are? The biological significance of EPCs What they are? Fadini et al, Diabetes Care 2007

The clinical significance of EPCs Disease Marker – Cardiovascular risk The clinical significance of EPCs Disease Marker – Cardiovascular risk Fadini et al. Eur Heart J 2006 Fadini et al. ATVB 2006

The clinical significance of EPCs Disease Marker – Pulmonary diseases The clinical significance of EPCs Disease Marker – Pulmonary diseases Fadini et al. Stem Cells 2006 COPD RLD

The clinical significance of EPCs Disease Marker – CVD vs Pulmonary disease The clinical significance of EPCs Disease Marker – CVD vs Pulmonary disease Fadini et al. AJRCMB 2006

Fadini et al. Eur Respir J. 2010